Leadership | Company | Chordia Therapeutics Inc.

Chief Exective Officer	Hiroshi Miyake	Hiroshi Miyake (Ph.D.) is a co-founder of Chordia Therapeutics and he has served as President and CEO and acted as a member of the board of directors since Chordia’s incorporation in November 2017. He has over 20 years of experience in drug discovery and his team has delivered programs to the clinical stage six times. Before the foundation of Chordia, he served as the site head of the oncology drug discovery unit at Takeda Pharmaceuticals. He earned his B.S. from Osaka University and his Ph.D. in Pharmacology from the University of Tokyo.
Chief Scientific Officer	Daisuke Morishita	Daisuke Morishita (Ph.D.) is the Chief Scientific Officer at Chordia Therapeutics and leads research initiatives developing cancer treatments that change lives. Prior to founding Chordia in November 2017, DAISUKE spent ten years working on oncology therapeutics at TAKEDA pharmaceutical company, focusing on cancer-related RNA networks. As the industry-academia collaboration representative at TAKEDA, DAISUKE led the CTX-177 drug discovery research as the representative of industry-academia collaboration programs in TAKEDA. Through the success of CTX-177 research, DAISUKE has been invited and held positions as an associate professor in Kyoto University to pursue a therapeutics strategy in cancer-related RNA network and an adjunct professor in Kumamoto University and Nagoya City University to produce next generation anti-cancer drugs. DAISUKE received Ph.D. in oncology from the University of Tokyo.
Chief Medical Officer	Yoshiyuki Tanaka	Yoshiyuki Tanaka has served as Chief Medical Officer (CMO) since his appointment in January 2026.Prior to joining Chordia, he spent approximately 20 years at MSD K.K. (formerly Banyu Pharmaceutical Co., Ltd.), where he worked across a broad range of therapeutic areas including vaccines, infectious diseases, and oncology. He successfully led and contributed to numerous drug development programs, encompassing clinical development from Phase 1 through Phase 3, safety evaluation and management, regulatory strategy and approvals. Most recently, he served as Head of Oncology Clinical Development, directing oncology drug development in Japan under global development strategies.Prior to joining the pharmaceutical industry, he worked as a physician and researcher in oncology at academic medical centers in Japan, and completed research training at Washington University School of Medicine in St. Louis.He received his M.D. and Ph.D. from the Faculty of Medicine, Tottori University.
Chief Administrative Officer	Yoshihiko Satoh	Yoshihiko Satoh, Ph.D. MBA has served as CAO and leads corporate management of Chordia. He contributed the licensing agreement with ONO Pharmaceuticals in 2020. Prior to joining Chordia in April 2018. He has over 10 years of experience in pharmacology on oncology therapeutic areas at Takeda and Astellas pharma. He received Ph.D. in Physiology from University of Kumamoto and Executive Master of Business Administration from NUCB Business School.
Chief Financial Officer	Masaru Okatani	Masaru Okatani has served as CFO since his appointment in September 2025. Prior to joining Chordia, he worked in audit at a major accounting firm, followed by M&A advisory, and later led corporate management as head of the management division, overseeing operations and driving financial strategy and execution. He brings broad financial knowledge and management experience, promoting capital policy and investor engagement to enhance corporate value. He graduated from Hitotsubashi University (B.A. in Economics) and earned an MBA from the National University of Singapore. He is a Certified Public Accountant.